NEW YORK--(BUSINESS WIRE)--New York based enterprise artificial intelligence startup WhizAI today announced a $1.1 million round led by strategic partner Trigyn Technologies, Inc (wholly owned subsidiary of Trigyn Technologies Limited, a company incorporated under Indian Laws and listed on BSE and NSE) with participation from angel groups and existing investors.
WhizAI is a pre-trained AI-powered marketing and sales enablement platform for large enterprises. The company’s clients in manufacturing and life sciences are using the WhizAI platform to increase rep productivity, institutionalize sales best practices, empower marketing with AI powered analytics, and improve adoption of existing data and applications via seamless access in natural language on desktop and mobile.
“I'm thrilled to form an alliance with Trigyn as the new investment will help us further build out our AI platform, and the partnership will accelerate our customer acquisition," said Rohit Vashisht, co-founder and CEO of WhizAI. WhizAI is a proprietary AI platform built for large enterprises and can be deployed within the client’s firewall, integrated with multiple data sources, as well as maintained and customized by client’s IT team.
Mr. R. Ganapathi, the Chairman and Executive Director of Trigyn Technologies Limited said, "Trigyn is servicing clients world over with US being our primary market. Our clients are actively looking at AI solutions and we plan to work with the WhizAI team to bring a robust enterprise grade AI platform to our clients to help them improve productivity, information access and sales.
"WhizAI was founded in New Jersey in 2017 by seasoned entrepreneurs Rohit Vashisht, Amitabh Patil and Aaron Carlock, who have previously built venture backed companies with successful exits. The management team has a proven track record and expertise in AI, ML and enterprise software that is being used at Fortune 500 clients. WhizAI’s current clients include large manufacturing and life sciences companies and it has raised $1.6M to date.
About WhizAI: WhizAI is empowering commercial teams at large enterprises with conversational intelligence through its pre-trained AI platform. We do this by providing seamless access to enterprise data, insights and workflows in natural language on desktop and mobile for improving marketing effectiveness and streamlining sales processes. Our proprietary AI platform is transforming industries to increase rep productivity, institutionalize sales best practices, empower marketing with AI-powered analytics, and improve adoption of existing data and applications.
About Trigyn:Trigyn Technologies, Inc. (TTI) is a Delaware Corporation headquartered in Edison, New Jersey with office locations in New York City, Washington DC, Toronto and Montréal Canada.TTI’s parent company, Trigyn Technologies, established in 1986, is a public multi-national Information Technology firm with 1,500 resources deployed in 25 countries across Asia, North America, Europe, and Africa. Trigyn has an established client base of major fortune 500 companies in diverse industries, Intergovernmental Organizations, and US State Governments. Trigyn’s service offerings include a rich history of implementing fully operational Unified Command & Control Centers, Smart Solutions, Internet of Things (IoT), Smart Utilities, Security, Surveillance and more. Trigyn is ISO 9001:2015, ISO 27001:2013 (ISMS) and CMMI Level 5 Certified. Trigyn maintains industry partnerships with Microsoft, IBM, SAP, EMC, TIBCO and other industry leaders and is listed on The National Stock Exchange of India Limited (NSE) and BSE Limited (BSE). Visit www.trigyn.com to learn more.
People also viewed
Customer Centricity and Digital Experiences which are Redefining Pharma
It is no secret that the pharmaceutical industry has historically flourished from blockbuster products with substantial brand equity, favorable pricing
Awash in Data, Yet Starving for Insights? Transform Life Sciences Commercial Teams with AI-Powered Analytics
Personalized communication is something the HCPs have come to expect. To do that, pharma sales reps need to know their customers well. In order to know the customer well, they need data. Enterprise pharma companies, however, have many data resources and lots of data at their disposal. In fact, there is a data explosion. So what do you do?
Readiness of Augmented Analytics for Life Sciences Commercial Teams
Demand for smart, agile, and near-instant commercial analytics in Pharma is rising. More contextual, continuous, and connected data and analytics are required to respond to more complex and uncertain business decisions.
Augmented Analytics is “On the Rise” on Gartner’s 2022 Hype Cycle for Life Science Commercial Operations
The Gartner® 2022 Hype Cycle™ for Life Science Commercial Operations introduces a new category, Augmented Analytics, this year. WhizAI is listed as a sample vendor in the Augmented Analytics category in this Hype Cycle. This summary report covers the following highlights.
Where Gartner Positions Natural Language Query on the Hype Cycle and What It Means for Life Sciences
Gartner® 2022 Hype Cycle™ for Natural Language Technologies (NLT) shows natural language query (NLQ) adoption is accelerating. WhizAI was recently recognized as a Sample Vendor in the Natural Language Query category in several Gartner Hype Cycles:
AI Powered Business Intelligence for Life Science Leaders: Save Time, Drive Adoption and Scale Faster
Today’s commercial teams must pinpoint top opportunities in markets across the country—or across the world—based on regulations, drug trials, market activity, competitors, insurance records, HCP preferences and affiliations, much more data than is humanly possible to manage.
Why Domain Expertise Is Essential for Life Science Analytics
Domain expertise matters. Consider this: Enterprises choose transportation and logistics companies that have created the specific types of services they need. Businesses seek professional services with experience in their industries and look for consultants with good track records in their markets. However, remember that domain expertise benefits extend to analytics platforms, particularly those deployed for life sciences.